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Abstract 
Chemical genetics has played an important role in linking specific G protein-coupled receptor 
(GPCR) signalling to cellular processes involved in central nervous system (CNS) functions. 
Key to this approach has been the modification of receptor properties such that receptors no 
longer respond to endogenous ligands but rather can be activated selectively by synthetic 
ligands. Such modified receptors have been called Receptors Activated Solely by Synthetic 
Ligands (RASSLs) or Designer Receptors Exclusively Activated by Designer Drugs 
(DREADDs). Unlike knock-out animal models which allow detection of phenotypic changes 
caused by loss of receptor functions, RASSL and DREADD receptors offer the possibility of 
rescuing “knock-out” phenotypic deficits by administration of the synthetic ligands. Here we 
describe the use of these modified receptors in defining the physiological role of GPCRs and 
validation of receptors as drug targets. 
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Abstract 
Chemical genetic has played an important role in linking specific G protein-coupled receptor 
(GPCR) signalling to cellular processes involved in central nervous system (CNS) functions. 
Key to this approach has been the modification of receptor properties such that receptors no 
longer respond to endogenous ligands but rather can be activated selectively by synthetic 
ligands. Such modified receptors have been called Receptors Activated Solely by Synthetic 
Ligands (RASSLs) or Designer Receptors Exclusively Activated by Designer Drugs 
(DREADDs). Unlike knock-out animal models which allow detection of phenotypic changes 
caused by loss of receptor functions, RASSL and DREADD receptors offer the possibility of 
rescuing “knock-out” phenotypic deficits by administration of the synthetic ligands. Here we 
describe the use of these modified receptors in defining the physiological role of GPCRs and 
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Introduction 
Muscarinic acetylcholine receptors (mAChRs) play key roles in many physiological functions 
in both the central and peripheral nervous system (Hulme et al., 1990). Furthermore, 
aberrations in muscarinic expression and/or signalling have been implicated in the 
pathophysiology of numerous disease states, and as such mAChRs represent therapeutic 
targets for an array of human diseases (Kruse et al., 2014b; Wess, 2004). Of the five mAChR 
subtypes (M1-M5), four crystal structures have been solved revealing a high degree of 
similarity within the acetylcholine binding pocket and, therefore, design of subtype selective 
pharmacological entities that target the same binding site as the endogenous ligand has 
proven challenging (Kruse et al., 2014a; Kruse et al., 2012; Kruse et al., 2013; Thal et al., 
2016). Hence, much effort has been directed toward developing ligands that target alternative 
(allosteric) binding sites on the receptor. Such allosteric modulators have the potential to be 
more subtype selective as the allosteric binding sites on GPCRs are less evolutionarily 
conserved (Conn et al., 2014). A number of positive allosteric modulators have indeed been 
successfully developed for the M1 and M4 muscarinic receptors including BQCA (M1 positive 
allosteric modulator) (Bradley et al., 2017; Ma et al., 2009; Shirey et al., 2009) and 
LY2033295 (M4 positive allosteric modulator) (Chan et al., 2008), which showed superior 
subtype selectivity and usefulness in animal studies. Despite these successes, allosteric 
modulators have their drawbacks, most notably, the ligands require the presence of the 
endogenous neurotransmitter to function. Therefore, in disease situations where ACh levels 
are depleted, the effects of allosteric modulators on receptor function might not be detected.   
Over the past fifteen years, knock-out animals lacking each of the five muscarinic receptor 
subtypes have been developed, which provided a wealth of information on the role of these 
receptors in the CNS (Wess, 2004). For example, M1 mAChR deficient mice show deficits in 
learning and memory tasks (Bradley et al., 2017) indicating a clear role for this muscarinic 
receptor subtype in cognitive function. Furthermore, knockout of M1 in parvalbumin-
containing neurons in hippocampal CA1 region also leads to impairment in working memory 
and cognition (Yi et al., 2014). Taken together, these data highlight CNS M1 mAChRs as 
therapeutic targets in diseases associated with impaired cognitive function, such as 
Alzheimer’s Disease and schizophrenia. However, such knockout models are limited to the 
detection of biological responses caused by a loss of receptor function and are unsuitable for 
identifying the consequences of or biological responses associated with receptor activation. 
Additional potential drawbacks associated with knockout models include cellular 
compensation and disruption of the basal ‘tonic’ neurotransmitter release, which may subtly 
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affect cellular/synaptic excitability. To overcome these limitations, researchers have 
developed more sophisticated approaches, which involve the use of chemical genetics to 
enable receptor activation in vivo with exquisite selectivity and precise spatiotemporal 
control. The premise of the chemical genetic approach is to modify the receptor such that the 
receptor no longer responds to the endogenous ligand but can be activated by inert drug like 
synthetic ligands. Such mutant receptors have been termed Receptors Activated Solely by 
Synthetic Ligands (RASSLs) or Designer Receptors Exclusively Activated by Designer 
Drugs (DREADDs). Unlike the mode(s) of action of allosteric modulators, which depends on 
the presence of the endogenous neurotransmitter, RASSL/DREADD receptor functions 
independently of the endogenous ligand. Expression of these modified receptors in place of 
the wild type muscarinic receptor theoretically should result in a phenotype similar to that of 
the receptor knockout. Administration of the surrogate “synthetic” ligand activates the 
RASSL/DREADD receptor allowing for the identification of cellular and physiological 
responses associated with activation of the mutant receptor. This approach can not only be 
used to establish the physiological responses and signalling pathways that lie downstream of 
a GPCR but importantly, this approach mimics the responses that might be expected if a 
receptor subtype selective drug were to be developed. Hence, this approach would enable 
assessment of both the potential clinically beneficial and adverse effects of receptor 
activation.  
 
Chemical genetic approach to generate muscarinic DREADDs 
The premise of chemical genetic is to engineer cellular signalling systems that can be 
employed to alter in vivo physiological and behavioural responses in a highly specific 
manner. Key to this approach is the availability of surrogate ligands that have favourable 
pharmacokinetic properties and are otherwise pharmacologically inert in normal 
physiological conditions. In addition, the genetic modification introduced to the receptor 
should render the receptor unresponsive to the endogenous ligand and does not produce 
unintended response in the absence of the surrogate ligands. Classically, chemical genetic 
approach employed rationally designed mutation of residues known to interact with 
endogenous ligands, such as the highly conserved aspartate residue in the biogenic amine 
receptors (D
3.32A in the β2-adrenoceptor and D
3.32
A in 5-HT4 receptor) (Claeysen et al., 2003; 
Strader et al., 1991). Although, these mutations reduced the affinity and efficacy of the 
endogenous ligands, the affinity and efficacy afforded to the synthetic ligands were 
insufficient to warrant in vivo study (Strader et al., 1991), and in the case of the 5-HT4 
5 
 
receptor, the mutation produced an unwanted constitutive receptor activity (Claeysen et al., 
2003). A second method, which involves domain swapping, was introduced. Here, the second 
extracellular loop of the κ-opioid receptor was replaced with that of the δ-opioid receptor to 
produce a chimeric receptor that displayed 200-fold reduction in the binding of the 
endogenous ligand, dynorphin, but maintained normal binding and activation by small 
molecule ligand, spiradoline (Coward et al., 1998). Conditional expression of this chimeric 
receptor, termed Ro1 in tissues such as the heart and salivary glands resulted in physiological 
responses that are consistent with Gi signalling through the κ-opioid receptor, such as 
reduction in heart rate and salivary secretion (Redfern et al., 1999). Despite these successes, 
Ro1 is not an ideal system as the surrogate ligand, spiradoline is pharmacologically active at 
the native κ-opioid receptor, which necessitates expression of Ro1 in a knockout background 
(Sweger et al., 2007). To circumvent these issues, Roth and colleagues employed directed 
molecular evolution and a yeast based growth assay on the M3 mAChR with the aim of 
evolving the receptor to respond to clozapine-N-oxide (CNO) and concomitantly eliminate 
the binding and signalling efficacy of acetylcholine (ACh) (Armbruster et al., 2007). CNO 
was chosen as a surrogate ligand due to its drug likeness and favourable pharmacokinetic 
properties. The ligand is also reported to be pharmacologically inert and hence less likely to 
produce off target effects (Weiner et al., 2004). This strategy uncovered mutations of two 
residues, one on TM3 (Y
3.33
C) and the other on TM5 (A
5.46
G) which significantly reduced the 
activity of acetylcholine but instead generated responsiveness to CNO (Armbruster et al., 
2007). Moreover, these mutations did not produce constitutive receptor activity, making 
muscarinic DREADDs an ideal tool for in vivo studies.  The residues that make up the 
DREADD mutations are also conserved among the five members of the muscarinic receptor 
family and analogous mutations in these receptors have resulted in the generation of 
DREADDs for all five (M1-M5) muscarinic receptor subtypes (Armbruster et al., 2007).  
 
Pharmacology of muscarinic DREADDs 
Early in vitro characterisation of the M3 DREADD showed that in response to CNO, the 
engineered receptor was able to stimulate G protein-mediated signalling pathways such as 
phosphorylation of ERK1/2, inositol phosphate accumulation and calcium mobilisation 
(Armbruster et al., 2007). In contrast, acetylcholine, the natural ligand for the M3 mAChR, 
showed significantly reduced activity at the M3 DREADD receptor. Further work on the M4 
DREADD showed that when expressed in neurons, the receptor was able to cause 
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hyperpolarisation and neuronal silencing, indicating that the DREADD is able to replicate the 
M4 receptor function in a native cellular environment.  
It is now widely accepted that different ligands binding to the same GPCR can differentially 
direct receptor signalling via one pathway in preference to another, a concept referred to as 
“stimulus bias” or “functional selectivity” (Galandrin et al., 2007; Stallaert et al., 2011). 
Given this, it is possible that DREADD receptors, activated by CNO may signal differently to 
the wild-type acetylcholine-stimulated receptor. It has therefore been imperative to 
thoroughly examine the signaling properties of the DREADD receptors in particular to 
determine if the DREADD ligand shows functional bias. In the case of the M3 DREADD 
expressed in cell lines, it was shown that no functional bias was observed in a range of 
cellular signalling assays including ERK1/2 phosphorylation, calcium mobilization, receptor 
phosphorylation, β-arrestin recruitment and receptor internalisation (Alvarez-Curto et al., 
2011). M3 DREADD expressed in neurons also did not display functional bias as similar 
afterdepolarisation and action potential frequency were observed in the M3 DREADD-
expressing neurons treated with CNO compared to wild-type neurons stimulated with 
muscarine  (Yi et al., 2014). Hence, activation of the M3 DREADD receptor with CNO 
closely reflects that of the acetylcholine-stimulated wild-type receptor.   
Despite the equivalence in the pharmacology of the acetylcholine-bound wild-type receptor 
versus a CNO-bound DREADD receptor, the allosteric interactions at these receptors might 
not be the same as allosteric ligands have distinct binding pockets with complex 
pharmacology. That this is the case is evident at the M4 DREADD. While acetylcholine and 
LY2033298 (an allosteric potentiator) display positive co-operativity with respect to binding 
at the wild-type receptor, the interaction between clozapine-like compounds and LY2033298 
at the DREADD receptor was neutral. Furthermore, LY2033298 could rescue acetylcholine 
responses at the M4 DREADD receptor a result which indicates for the M4 DREADD at least, 
that this chemical genetic approach could extend to the examination of physiological 
responses modulated by both allosteric and orthosteric synthetic ligands (Nawaratne et al., 
2008). Further differences in allosteric action at DREADD receptors was revealed by an in-
depth study investigating the action of the M1 mAChR positive allosteric modulator, BQCA, 
at wild-type and M1 DREADD receptors (Abdul-Ridha et al., 2013). BQCA is a positive 
modulator of ACh binding and function at wild-type M1 mAChRs, and does not engender 
stimulus bias (Canals et al., 2012). However, BQCA engenders stimulus bias at the 
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DREADD receptor, with the degree of co-operativity differing depending on the signalling 
pathway being probed. These studies indicate that clozapine derivatives can stabilize unique 
receptor conformations with BQCA at the M1 DREADD receptor to reveal significant 
differences in downstream signalling pathways. Hence, it might be possible to employ 
DREADDs to investigate signalling bias in vivo.  
In vivo applications of muscarinic DREADDs 
An alternative approach to delineating the physiological roles of GPCRs is to 
pharmacologically manipulate the activity of a given receptor using synthetic agonists or 
antagonists. However, development of subtype selective orthosteric ligands for GPCRs has 
proven challenging owing to the highly conserved binding pockets for endogenous ligands 
across GPCR subtypes. The DREADD approach provides a novel and powerful tool to 
overcome these barriers. As described above, the residues mutated to generate the M3 
DREADD are conserved across all members of the muscarinic acetylcholine receptor family, 
and as such a battery of muscarinic DREADDs have been created which have been used in 
numerous transgenic studies to control Gq/11, Gi/o or Gs signalling.  
 
Conditional expression of the Gq/11-coupled M3 DREADD in pancreatic β-cells using insulin 
promoter revealed a role for Gq/11 signalling in the acute- and second-phase insulin release, 
whereby CNO co-administration with glucose led to dramatic increases in in vivo insulin 
release (Guettier et al., 2009). Furthermore, in mice expressing M3 DREADD selectively in 
β-cells and maintained on a high-fat diet, glucose and CNO co-administration was found to 
improve glucose tolerance and in vivo insulin release compared to mice treated with glucose 
alone (Guettier et al., 2009; Jain et al., 2013). 
 
In addition to exploring a role for Gq/11 signalling in glucose homeostasis by driving 
expression in pancreatic β-cells, the M3 DREADD has been used to probe the function of 
Gq/11 signalling in specific CNS pathways. Targeting the M3 DREADD to agouti-related 
protein (AgRP) neurons showed that stimulation of AgRP activity can induce feeding and 
reduce energy expenditure in mice (Krashes et al., 2011). Furthermore, the M3 DREADD 
under the control of a tetracycline CAMKII promoter has also been selectively targeted to 
forebrain pyramidal neurons; in the absence of the exogenous ligand, these mice displayed 
normal physical appearance and behaviour. However, mice that were treated with CNO 
showed significant enhancement in locomotion and limbic seizures, unveiling a role for Gq/11 
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signalling in mediating locomotion and seizures (Alexander et al., 2009).  The usefulness of 
M3 DREADD in providing mechanisms of cholinergic driven seizures was further 
demonstrated by studies  on M3 DREADD expressed in parvalbumin-positive (PV) 
interneurons, a CA1 region of the hippocampus that also express the M1 muscarinic receptor 
(Yi et al., 2015). Chronic or continued administration of pilocarpine to PV neurons of wild-
type mice resulted in increased action potential, which developed into a state of 
depolarisation block and a deficit in GABAergic inhibition (Yi et al., 2015). This state leads 
to the onset of epileptic seizure-like activity. Interestingly these processes were mimicked by 
the M3 DREADD upon stimulation with CNO and was absent in the PV neurons devoid of 
M1 muscarinic receptor (Yi et al., 2015). Together, these data indicate that chronic activation 
of pyramidal forebrain neurons and parvalbumin-positive (PV) interneurons of the 
hippocampus plays an important role in the induction of epileptic seizures.        
 
Furthermore, the muscarinic receptor DREADD mice have been employed to demonstrate 
roles for Gq/11 signalling in learning and memory. Using a c-fos based transgenic approach the 
M3 DREADD was expressed in an activity-dependent manner in neurons following exposure 
to an environmental stimulus (Garner et al., 2012). This allowed for the subsequent re-
activation of a particular subset of neurons following administration of CNO, which formed a 
hybrid fear memory incorporating elements of an artificially-induced neural network. Taken 
together, these studies highlight the potential of these chemogenetic tools to remotely control 
the activity of Gq/11 signalling in vivo, in a manner that is selective and reversible.  
 
Muscarinic DREADDs have also been used as an approach to suppress neuronal signalling; 
these studies employed an M4 DREADD, which is coupled to Gi/o proteins and induces 
membrane hyperpolarization by activation of G protein inward-rectifying potassium channels 
(GIRK) (Armbruster et al., 2007). In these transgenic mice where the M4 DREADD is under 
control of a CAMKII promoter, CNO significantly impaired consolidation of contextual 
memory in the hippocampus by inactivating hippocampal neurons (Zhu et al., 2014). 
Furthermore, the use of viral vectors allowed for brain-region specific control of neuronal 
signalling, and showed that inactivation of ventral but not dorsal hippocampal neurons 
suppressed contextual memory consolidation, highlighting the use of DREADD technology 
to anatomically define sub regions of the brain, which are central to the behavioural effects 
(Zhu et al., 2014). This is further evidenced by studies in which expression of the M4 
DREADD receptor is driven selectively in the medio-dorsal thalamus (MD) revealing that 
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subtle decreases in activity in the MD was sufficient to induce profound impairments in 
cognitive tasks associated with the prefrontal cortex (Parnaudeau et al., 2013). These studies 
provided direct evidence linking reduced MD activity and prefrontal cortex-dependent 
learning and memory processes, a mechanism postulated to underlie cognitive impairment in 
schizophrenia. Neuronal silencing through expression M4 DREADD in PV interneurons in 
the medial prefrontal cortex has also been associated with helplessness and enhanced 
susceptibility to stress (Perova et al., 2015), highlighting a role for this region in mood and 
depressive disorder. Furthermore, targeting of M4 DREADD into motor cortex using a 
CAMKIIa promoter and adeno-associated delivery system, has also uncovered a role for the 
inhibition of seizures (Katzel et al., 2014; Krook-Magnuson and Soltesz, 2015). Acute 
administration of pilocarpine and epileptic promoting toxins (picrotoxin and tetanus toxin) 
locally into the cortex resulted in increased spiking frequency of Morlet-wavelet EEG spectra 
and the development of acute seizures. M4 DREADD activation in this brain region by CNO 
immediately after pilocarpine injection reduced the spiking frequency and seizure severity 
(Katzel et al., 2014).     
 
Taken together, these approaches highlight the use of chemogenetic technology to reversibly 
and non-invasively control G protein signalling to probe physiological functions of specific G 
protein pathways and the contribution of certain brain regions in disease states. Despite this, 
muscarinic DREADDs are yet to be fully exploited for the physiological functions of specific 
muscarinic receptors. At present there is only one publication relating to the use of 
DREADDs to probe the muscarinic receptor activation in vivo (Butcher et al., 2016). In this 
study, a novel mouse model was generated in which the gene coding for the M1 mAChR was 
replaced with an M1 DREADD C-terminally tagged with a human influenza hemagglutinin 
(HA) epitope (Figure 1). Thus, expression of the M1 DREADD is under the control of the 
endogenous M1 mAChR promoter and, therefore, the DREADD receptor will only be 
expressed in the cell types in which the native receptor is expressed and at physiological 
expression levels. Administration of CNO to these mice resulted in an increase in 
phosphorylation of serine 228 of the M1 DREADD receptor, a phosphorylation event that is 
used as a biomarker for receptor activation (Butcher et al., 2016). Further behavioural and 
electrophysiological work on this mouse model together with the M4 DREADD mice which 
are already generated (see Figure 2 for pharmacological characterisation) will provide a very 
powerful tool to selectively and reversibly manipulate specific muscarinic receptor subtypes 
in vivo to define their physiological and pathophysiological functions.  
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Caveats of chemical genetic approaches 
While chemogenetic approach has afforded the ability to selectively target and activate 
particular signalling pathways and mAChR subtypes in vivo which would otherwise be 
challenging to achieve using directly acting pharmacological agents, there are several 
disadvantages associated with using this approach. One such disadvantage is that the 
temporal pattern of activation of the DREADD receptor might not be the same as the native 
receptor. For example, acetylcholine, the endogenous ligand for mAChRs is rapidly degraded 
by acetylcholinesterase after being released into the synaptic cleft, hence the ligand has a 
short duration of action. Furthermore, the release of acetylcholine is intimately linked with 
membrane potential and physiologically released in short bursts and pulsatile manner. 
However, CNO, the surrogate ligand for the muscarinic DREADDs is metabolically more 
stable relative to acetylcholine and hence likely to have a longer lasting effect on receptor 
activation. Indeed it has been shown that despite the fact that CNO levels in the plasma peak  
30 min intraperitoneal administration, the physiological effect of the compound was still 
observed 6 hours later (Alexander et al., 2009; Guettier et al., 2009). This prolonged duration 
of action of CNO might not be useful for studying short-term effects of neuronal activity on 
behaviour. For better temporal control of neuronal responses, it may be necessary to 
complement DREADDs with optogenetics. Optogenetics utilise light to activate 
photosensitive receptor proteins and GPCR ligands, and the pattern of activation can be 
controlled such that it mimics action potential. Examples of optogenetic approaches include 
photoswitchable tethered ligands, which are otherwise inert and can only bind to the modified 
receptor when illuminated and optoXRs, optically sensitive chimeric proteins consisting of 
rhodopsin and the intracellular loops and C-terminal domain of GPCRs (Spangler and 
Bruchas, 2017). Although optoXRs for muscarinic receptors are currently unavailable, a 
photosensitive dualsteric ligand has recently been developed for M1 muscarinic receptor 
which may be useful for probing the in vivo physiology of this receptor in the brain (Agnetta 
et al., 2017).     
 
Several studies have also indicated that in some species, including non-human primates, 
guinea pigs and certain strain of rats, CNO is reverse metabolised to the active parent 
compound, clozapine (Chang et al., 1998; Jann et al., 1994; MacLaren et al., 2016). This may 
limit the application of CNO-dependent DREADDs to only certain species and the 
translational potential of the technology. This has facilitated the development of novel 
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ligands with lower risks of being transformed into active metabolites such as compound 21 
and perlapine (Chen et al., 2015).  
 
The majority of studies employing chemical genetic approaches were performed with 
DREADD receptors that have been overexpressed in tissues and not under the control of the 
endogenous promoters for muscarinic receptors. In this context, the physiological effects 
observed in these studies reflect the outcomes of the signalling pathways activated or 
inhibited by the DREADDs, but not necessarily related to the physiological roles of the 
endogenous muscarinic receptors. To utilise the DREADD-based chemo-genetic approaches 
for elucidating the physiological roles of muscarinic receptors in vivo, these DREADD 
receptors must be expressed in tissues at physiologically relevant levels under the control of 
the endogenous muscarinic receptor promoters. Indeed, studies are beginning to emerge that 
use just this approach (Butcher et al., 2016) and although still in their infancy, these 
muscarinic DREADDs will provide a very powerful tool to selectively and reversibly 
manipulate the activity of specific muscarinic receptor subtypes in vivo thereby defining their 
physiological and pathophysiological functions.  
 
Conclusion 
There is now a very large body of data that have used chemical genetic approaches to define 
the signalling pathways that drive physiological responses. It is now also possible to replace 
wild type receptors with receptors that respond only to synthetic ligands. These engineered 
mice will not only allow for an understanding of the physiological pathways driven by 
individual receptors, but importantly allow for the first time, investigation of the clinically 
important outcomes of ligands that selectively activate a given GPCR subtype. In addition, 
this approach will also inform us as to the adverse “on-target” effects of receptor activation. 
Only time will tell if these DREADD receptors will impact significantly to validating GPCR 
targets but there is no doubt that this technology will increase in use to reveal the 
fundamental biology of GPCRs.     
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Figure legends 
 
Figure 1: Targeting construct for the generation muscarinic receptor (M1 subtype) 
DREADD. The gene encoding the native M1 muscarinic receptor was replaced by the 
DREADD construct using homologous recombination. Under this scheme, expression of the 
DREADD receptor is controlled by the endogenous muscarinic receptor promoter (taken 
from Butcher et al 2016). 
 
Figure 2: Pharmacology of M4 DREADD receptor. Wild-type muscarinic M4 receptor 
activates ERK1/2 phosphorylation in response to the endogenous ligand ACh but does not 
respond to the synthetic ligand clozapine-N-oxide (CNO) (A). In contrast, the M4 DREADD 
gains responsiveness to CNO but loses ability to respond to ACh (unpublished data). 
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